SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Escalating geopolitical tensions in the Middle East, including drone strikes on a major Saudi oil refinery and fears of a Strait of Hormuz disruption, are driving conversation around Indonesia Energy Corp. The community highlights the stock's low float and potential for a short squeeze, recalling its significant moves during prior global energy market volatility.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending following a trading halt prompted by its acquisition of key BrewDog assets and a new U.S. licensing deal with Carlsberg, igniting investor debate. While some hail these beverage sector moves as strategic expansion ahead of potential cannabis rescheduling, many criticize management's past acquisitions and express concern over potential dilution.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is trending amid significant volatility, recently impacted by an earnings miss and a government contract renegotiation, which some in the community view as an overreaction. Nevertheless, sustained discussions highlight AVAV as a crucial drone technology leader, positioned to benefit from escalating global defense spending and bolstered by recent positive analyst coverage.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings (RCAT) is trending amid heightened Middle East tensions and reports of increased drone warfare, fueling speculation about rising demand for its defense drone solutions. The community is actively discussing the stock's potential for defense contracts, including its involvement in the Drone Dominance Gauntlet, alongside ongoing debates about its revenue trajectory and susceptibility to short squeezes.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas is trending following its $10 million strategic investment and partnership with World View to develop multi-domain intelligence, surveillance, and reconnaissance solutions for defense. The community is actively discussing how this positions the company to benefit from escalating global demand for drone and counter-drone technologies, amplified by high short interest fueling squeeze speculation.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global (VG) is sharply trending after a strong Q4 earnings report highlighted triple-digit revenue growth and a new LNG supply agreement. The community is abuzz with expectations of a major short squeeze, driven by escalating geopolitical tensions affecting global LNG supplies and a consensus that the stock remains significantly undervalued amidst growing demand for U.S. energy.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending amid intensifying interest in optical interconnects following major industry investments, with the community highly anticipating its disruptive wafer-scale technology to be pivotal for next-gen AI data centers and expecting imminent partnership announcements from 'even bigger' players.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending after announcing positive Phase 3 SOL-1 trial results for AXPAXLI in wet AMD, demonstrating superiority over Eylea and offering a significantly reduced treatment burden, which the community sees as a potential "game-changer." Despite a market sell-off, investors are actively discussing high analyst price targets and persistent acquisition rumors from Sanofi, anticipating further upside as detailed data is presented at upcoming conferences and a regulatory filing approaches.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is trending as recent US-Israeli strikes on Iran and subsequent regional retaliation ignite community discussions over potential disruptions to global oil supply, especially concerning the Strait of Hormuz, driving speculation of significantly higher oil prices and market volatility.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is a top trending stock as escalating Middle East tensions, including reported closures of the Strait of Hormuz and attacks on major oil and LNG facilities, ignite fervent community discussion. Traders are sharply divided on whether these supply disruptions will lead to a sustained energy price rally, significantly benefiting XOM, or if the initial surge will quickly fade.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Kazia stated that in murine triple-negative breast cancer preclinical models, NDL2 reduced primary tumor volume by 49% as monotherapy.</li><li>In combination with the anti-PD-1 therapy, the treatment reduced the volume of the primary tumor by 73%.</li><li>In patients with lung metastases, Kazia stated that NDL2, combined with anti-PD-1 therapy, reduced the primary tumor’s volume by 50%.</li></ul><p>Kazia Therapeutics Inc.’s (KZIA) shares rose more than 6% in Friday’s pre-market trade after the company announced new preclinical and translational data for NDL2, a protein degrader.</p><p>The Sydney, Australia-based oncology-focused pharmaceutical company stated that across multiple preclinical models and patient-derived samples, NDL2 demonstrated reversal of immune exhaustion, suppression of metastatic biology, and enhanced anti-tumor activity. This includes the combination of NDL2 with anti-PD-1 therapy, which uses monoclonal bodies such as nivolumab or pembrolizumab to block the PD-1 protein on T-cells.</p><p>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/KZIA">Kazia Therapeutics</a> was in the ‘bullish’ territory at the time of writing, while message volume was at ‘high’ levels.</p><h2 class="st-heading-2">Highlights Of New NDL2 Data</h2><p>Kazia stated that in murine triple-negative breast cancer (TNBC) preclinical models, NDL2 reduced primary tumor volume by 49% as monotherapy. In combination with the anti-PD-1 therapy, the treatment reduced the volume of the primary tumor by 73%.</p><p>In patients with lung metastases, Kazia stated that NDL2, combined with anti-PD-1 therapy, reduced the primary tumor’s volume by 50%.</p><p>The company added that no toxicity or hemolysis was observed, while noting that the immune checkpoint function at the cell surface was preserved, and the plasma stability was favorable.</p><h2 class="st-heading-2">What Is NDL2 Aimed At?</h2><p>Kazia is currently developing the NDL2 protein degrader to selectively eliminate nuclear PD-L1 (Programmed Death-Ligand 1).</p><p>PD-L1 is a protein found on the surface of many cancer cells as well as some normal cells. The protein helps these cells evade the immune system.</p><p><a href="https://stocktwits.com/symbol/KZIA">KZIA stock</a> is down 6% year-to-date and 12% over the past 12 months.</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sofi-stock-rises-after-sofi-technologies-reports-1b-quarterly-revenue-first-time/cmySKHPR4ST"><strong>SOFI Stock Rises Pre-Market After SoFi Technologies Reports $1B Quarterly Revenue For The First Time</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Representative image of a trending stock chart.

KZIA Stock Is Rising Today — What Does Its Data For Nuclear PD-L1 Degrader Show?

Kazia stated that across multiple preclinical models and patient-derived samples, NDL2 demonstrated reversal of immune exhaustion, suppression of metastatic biology, and enhanced anti-tumor activity.

Equity

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear...

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer Kazia Therapeutics Reports...

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End Kazia Therapeutics to Participate in J.P. Morgan Healthcare...

Is the Market Bullish or Bearish on Kazia Therapeutics Ltd?

Kazia Therapeutics Regains Full Nasdaq Listing Compliance

Kazia Therapeutics Regains Full Nasdaq Listing Compliance Kazia Therapeutics Regains Full Nasdaq Listing Compliance PR Newswire SYDNEY, Dec. 22, 2025 Restoration of Nasdaq compliance follows $50...

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations...

What's Going On With Cancer Firm Kazia Therapeutics

Kazia announced a private placement of $50 million in equity securities. Proceeds will fund clinical development and extend cash runway.read more...

Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities PR Newswire...

<ul class="summary-bullets"><li>The patient remains on therapy and under active clinical monitoring, the company said.</li><li>In October, Kazia had announced that it observed an 86% reduction in tumor burden after only three weeks of treatment in the same patient.</li><li>Kazia also raised concerns on Tuesday regarding a potential suspension or delisting of its shares from the Nasdaq.</li></ul><p>Shares of cancer drug developer Kazia Therapeutics Limited (KZIA) were in the spotlight on Wednesday after the company said that a stage IV triple-negative breast cancer patient treated with a combination of its lead program Paxalisib with Pembrolizumab and standard chemotherapy has achieved an initial immune-complete response.</p><p>An immune-complete response means the complete disappearance of all signs of cancer following immunotherapy. It is also known as complete remission.</p><p>KZIA shares traded 42% higher on Wednesday morning at the time of writing.</p><h2 class="st-heading-2">Data And Takeaways</h2><p>As per Kazia, complete responses in stage IV metastatic TNBC are exceedingly uncommon and may suggest enhanced biological activity of the combination regimen, warranting continued follow-up.</p><p>In October, Kazia had announced that it observed an 86% reduction in tumor burden after only three weeks of treatment in the same patient. After about three months of therapy, a scan performed demonstrated complete metabolic resolution of all previously identified lesions, consistent with an initial immune-complete response, the company said.</p><p>The patient remains on therapy and under active clinical monitoring, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/kazia-therapeutics-achieves-initial-icr-immune-complete-response-in-metastatic-tnbc-and-delivers-q4-business-update-with-breakthroughs-across-breast-cancer-immuno-oncology-and-gbm-regulatory-strategy-302618635.html">added</a>. Kazia now plans to conduct a follow-up scan to confirm the initial scan.</p><h2 class="st-heading-2">Executive Commentary</h2><p>"Observing an initial complete response in a patient with metastatic triple-negative breast cancer is an extremely encouraging clinical finding," said CEO John Friend.</p><p>Paxalisib was licensed from Genentech in late 2016 and is being developed to treat multiple forms of cancer. The company now intends to request a meeting with the U.S. Food and Drug Administration to discuss the overall survival Paxalisib findings from its completed clinical studies and to discuss the elements needed for an application submission for Paxalisib in newly diagnosed glioblastoma.</p><h2 class="st-heading-2">Delisting Concerns</h2><p>Kazia on Tuesday also raised concerns about a potential suspension or delisting of its shares from Nasdaq, as it is not in compliance with certain listing rules. The company said it intends to request a hearing before a Nasdaq panel in a timely manner to stay any suspension or delisting action pending the outcome of the hearing.</p><p>The company is now also evaluating corporate and market-based options to regain compliance.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KZIA">KZIA stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.</p><figure class="image"><img style="aspect-ratio:585/56;" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAkkAAAA4CAYAAADpYWx5AAAQAElEQVR4Aex9C1RU1/nvb3jIIAQGEnXGaHTyFGLaYGyjtCaV/E0r1NsIecLSrojaKCS3Rs29SY2rK4vkv5pAchtFUxXT2GBeimkomKsXspLUV6KSRAvGR0YjZiagDCrIIAPc7zvzYAZmhhkEAf1mncfe+3vsvX/nnB/f3vvMENQuH0FAEBAEBAFBQBAQBASBLggEQT6CgCAgCAgCgsAVhYB0RhDoHQR8BkkXL7agvv48amrq8MMPtbILBnIPyD0Q0D3A3MEcwlzSO5TV4YV9sm+uQ/hJ+FnuAbkHArkHmDeYP5hHOlila8prkMTGZvM5hISEICYmCjrddRg5cpjsgoHcA3IP+HUPMGcwdzCHMJcwp3SlIPcSf3Psi32yb66D6xJ+En6We0DuAX/uAeYL5g3mD+YR5hNv3BPkSXDmzFmlePjwWERGhiM0NAQqlUopk4MgIAgIAv4goFKpFO5gDmEuYRsHt3C6p7vDB/tk38JPPUVS7ASBqxMBlcp/buoSJHFEFRwcBI3mGgmMrs77pwe9FhNBwDcCKpVK4RTmFuYY39repWzLPoSfvGMkEkFAEPAfAZXKNze5BUm8NtfcfBHR0ZH+1yCagoAgIAj4iQBzC3MMc42fJk41tmFb9uEslIQgIAgIAr2AAPMK8wvzjNMdJdyCpAsXLIiIGCozSASMbIKAIND7CKhUKoVjmGsC9c42wk+Boib6goAg4A8CKpVnbnILkjiCCgsL9cef6AgCgoAg0CMEmGOYawI1Zhu2DdRO9K86BKTDgkCPEGB+YZ5xNXYLkqzWVoSEBLvKJS0ICAKCQK8iwBzDXBOoU7Zh20DtRF8QEAQEAX8QYH5hnnHVdQuSWKBSybfYGAfZBQFBoG8QUKm8cIwf1alUPbf1w72oCAKCwFWMgErVlV+6BElXMT7SdUFAEBAEBAFBQBAQBJwISJDkhEISPURAzAQBQUAQEAQEgSsSgQEeJLWi5mQtrFck9NIpQUAQEAR6A4Fq7NyyGyd7w5X4EAQEATsCtlOvBEmNVVuxfsVqrFhF+xubUH70gs17D46HSt7Dzlq7Yf2X2F5Uji/q7fm+OtXuRmHJ4b7yLn4FAUGgnxCo2fEeVq3dhkNtLg048SnWv/FeB8+4iPo7af26GKuKK92acXbPJrz1icmtzD1jxg/HTahzL5ScICAI9AIClx4ktR3A1m3ncPucBXhyIe3pCbghfGgPm3YOdWeaYbHazTWTkPE/H0Gixp7vq1OdGXVNzX3lXfwKAn2CQHs70ET37fnzF2A2n8fp0/XKP6M2mc7AaKyl/TR+/PEMamvN4H/lcfZsAxoamtD5K6590rgB4rS1uRkh7dU4eKCjQYe+OQELmjt4pkPU76mQW3WIPn4Ch5wtOYf/fGvGcL3WWSIJ3wiItP8RuJK46dKDJCIht/Ai6ibcfL39IrWZ8fWWDVj1xlqsWrMJO0/Zynm2qPyrHXh37Vqs+OtaFO60jZK4fJ+ZSGEL6SszO4dR/MZWO2FQ+u1y7CnfhDUrV+I1Hh3+WInit9jHareRVuPRTxXfq1atxXry08jV8mxR8V4cLKH2OOybSMDl24/Beurf1M6BObqkVsomCCgItLRYce5coxL4XLx4EWfPnsf5840ULFmU4Ie/vtrW1gYmqXY6tLa2gW34l2QbG5vItgF85qDJTM8aB1mspzi/Qg8hUVGoO3LA1ru2wzhUE4XhruO4xmMof3c9Pf/EOwXENwphAMYdxDXEIaveWI93P69Wlv09ldV9tRVvEZetWkkz6Rs+hdExa3Vqt42HmP+U/T3b7JWX+pQGht8KfXQ1DMeVHEXBh2E4Owr6sZR38Cm3adUGFFd5mLFnPnt7N2pInTeeSSvcYZua53TxjgP48E3mTObdapz8fBPWr1qJ194oxtf2fsNRD7fZhbfZn+yCgDcEmGeuRG669CApfCKSJgJfrFuLt0r24uS5DggPlWzCvuj7sfCJeVg4U4cjZbvB/zq3uakWh07EYHrmPDw5Kx7WfRVKIDQuZQZuj4zC7TNJP+VWctSMZhop24IwStdWo+aGZMzPzsb04cew9V8m3JlOPub+DCHffImDZIG63di0zYw4Kl+4cA5+fvFTlH9LAivZH/8WdT/JwEK7/Z791Nhhk5AxZRRw/S+pnTRrNYx0ZRMEBhgCHPzU1Z1TgqOGhgv2wKcFYWFDAm7pkCFDwEETB0gcKNXU1CmBE8VUAfvqPYM+9DT8JujN32IfD4q+JQ64fhRiWxz1mbFzcznq4h6l538e5k+yorz8MAkrsWcvcDdz1xNz8OCkUQiBpzIgTJeAB4jLFmYvwLToSmzbRbyCWpR/XIlr7ycuIx/3jw7D6P9ifvFWH1WpbFG4/aahOHm4Wsk1HziGurE3YRzlDpW8i33XEJ8uJJ+/T0Bj2Rbs7LzGxjxHA9dW0ueNZ9Kam205Th8/0Yx7fk+cyby7pxh7yN+chdmYMdqEfV/YgilvvM3+ZBcEOiNwpXPTpQdJhJjuF4/gySdmYDy+RTGNUmwzQydgOBWMWLUR+/ZXYN9JK8IaTHAMkIaPjUc01x4bhQh+sOHPJwo33DxUUYy+JgLR+niMDqVsRBjC2lrBVNB89ATO0cjR+i3Vuf8bNA8JQ+0p20wVho7CLaODyQBg+9ZmDyMxRSoHQWBgINDa2kpLaeeUZTSLxTZccLSMA52eBElB/Nw5nNCZZ5t4KY6DJQ6cqOgK23QYf9MFHPnPBRw6bMboOBoUOXrYdIxmaqIQ3UpBFPHU100hUNcYYcRY6K83Y8+mT3HQ2IwQ5hmPZUDEiGFoPV6B8pJifHUasPEKsxHx0jVQPsHBzThXR9fPa32KmnKIjhuLsJPHqA3Aoe/rMPZWHjAyn0Zg7E/ty24Rd+DOMedgOEo+FSv/DhFaChD5+scS70KHW+6MUgwjwsOAdm4z1xPslbcVZTkIAoTA1cJN/LhQd3thC9PirhSapfndGDR+8w0MaIa1xdVvFG6ZlIDRrkV9kLbQcoSbW90d+PltMW5Fkuk9BMRT3yHAy2g//lhHS2me/xDy9HZoaEhADQgJCaZlOcdLf+6mDtLjd5t4dOguHdw53Z03ofnwNhw8Owbjx7j0pdkKNzSCtPjppNsQi6H46YM0gzQxAoZttES/pZIYzVMZzQy9vR5bj4bhlin34159hN25FncnhOHrze/hwy3v4ZOaW2nGPQzwWp/djE+xNxFPVsNQdwBHTGNxy21cyHwaDHUopzt2a4vne6NDI9AU1+Nqc3l427VGSQ98BK4mbrr0IOnUXnz2H55edrmwoWFQYwxGDruAxpDbcNeEBNt+5xgiHxc9j0krWts8CvwqjB6lQ9gFK2LvdNSZgPHXh3Vvewl1du9cNAQB/xHgAKW21gx+Ibs7Kw5sgoP9f4zDaHmOZ6B8+b14sUVZ1mtsbPKlNrhksfHQt1SjUf8T6FxbrhmFkWGNsMba+YK5Kk6LMLTSIC8YsTdOxIzfT8Lw74/hiMeyavxgpgHi/TSrHRWGxiZH0HIOX1e24q60BzD1vgcwZ/a90PFl8lqfa6O0iNO3wlB+DDWjbUttUPjUDMPhCzbFthMwGMMwcpRtJshWSMcRFN41mFGj8NkF1JxupMJAtjE95O1A6hDdwYrAVcRNzkvEj60z06OEJgbWr9/DipVrlRcfV/yrFvr7JhERheGuGfcj6uu3sGrDh9i0YT3WlByGg0I810XkcGMIDhaRr3d39+wrrWOSMON2M7au2oBCGsEpX/U947k2ZylNZ+trPsWKN2hEyO8vOQWSEAQuLwIcoJw+bVbeOfKn5ubmwN5LCg0NBRNdd775ZW5egquvP9+d6iCRx+CeR2fjwUkxndo7CtNS4lH38Wqs31iMwoK1KNxtBmorsOnN9XhrE5ftRuNPfobxnsowCvphJmwveA+FbxWiqmmo3X8URg9vxJ6NxEO0r3rzPRR/fgyNpO+xPrh/dDeNQuNJI0YSN9kkrnxaiPWrtqHu9mRMU2bFYhAdUY19n5uAoFsx/gYjyvnl7je2oCYi1mbu99G1Hn9522/nojiIEbhauenSg6SIm5CUPg9P/iEDGemz8WR2BqaNtc/cRNyKGfMWYH5aEqY/NgfzZ9xKIzTQNHY2Hvwp7J878OCiB+DI6qbOxqL5szH/0Uk06+Qqc00DuqTZmJNkX59HJ9kvHsHChY/gtzyCo3PitVSV7l7MyaTRHCV5c7MPj8cD2dTOx+dg+m0slV0QuPwI8PtAvNTV1tbud+XNzRcDenm7vV2ZYvDb/4ULFuXnA9oH6Vvdbs95WBQilOUqLZIyZyPJMaV0/SRkPLEAGb+9Fw8+Pg8ZiRRIDZuIR+fPQcb0e/HA7Hn4/VQt4KkMMbjr0XmY/9B0PDgrAzMezLDxUtthfHVqFB7gl6yfIPnDk6A+vAN7jAS9p/qo2G2jwd78RQvwQJxLqZNPZyCD/Gb8gtqkiCnQm7sAs5V8GMbPXICFsx9B5nzi4pRHbO0hPTcsOnOmK58660ly421yMfA3aWGfIHA1c1NQryEaOhTRNN3syV9IhIOcPEk9lIWFIbA3LTz4CArz2h54/ATTHxvIRxDoFwR4aYu/aRZo5fzSdVhYKKKjIxETE4XrrtNg+PBY6HTXKTunuYxlGs014OW5QOvgQIx/MmCwBkr+9jcsKgphQe7anrjLU1kX2+ZGWnq7gLp6fhkaaD1nRE1rDIa7/OZbFxv3qr3muP7O7URQMEJc2t5T366Vcj22oNK1VNJXGwJXOze5PFZX26WX/goCAwMBnq3hpa1AWjN0qFoJiDgYCgoKQkREOMLDwzBkSCj45WyVSgWVSqWkuYxlbBMVFYlhw2IQGTkUwcFBflfJU+0cKPltEJjilacdnoAH08ag5tNSfLilGFu/DqHlvhkYH37ldVV6dOUiINwE+M+SV+59ID0TBPoNAX4/KJAAiV+8HjEiFhqaFeLgpycNDw0NQVRUBEaMuJbOkUowBT8+HCjxj8X5oSoqhEDIiARMnzkDD/D+m4kYHUWFsgkCgwQB4SbbhZIgyYaDHHuCgNhcEgK8fFVXdxZ87s5REM0WxcRcg2uvjaYZoODu1P2WR0aG0/JcDC01D/HLhn/Ikpff/FIWJUFAEBiUCDAnCTfZLl2Q7SRHQUAQuNwI8AwSj9a6qzckJFhZIgsPV3en2iN5cHCwEnzxkp0/Dszm8+B3ofzRFR1BQBAYfAhc7dzkesUkSHJFQ9KCwGVCoK2tDRbLxW5r4yU1focoOLjvH1V++dufQInb3tRk6bbtoiAICAKDDwF+voWbOq5b3zNvR12SEgQEATsC/GvZI0bEKi9c24u6nDhA4uU1lUrVRdZXBd0FSiEhITTrpMHZtiZ8V2fqq2aIX0GgBwiISW8gINzkjqIESe54SE4Q6HMEmIT4m2L8m0j8rTP+mj4HRK4V88xRbGy03y9Vu9peapoDJX5B3NVPUJBK+ZmBzUxhZgAAEABJREFUyJihWLGnGP+19jnkfrbZVUXSgoAgMMgREG7qegF7JUiynDbBZOq01w+u6XjD6hToRqcg/3hXkHyVuPe9HoH2uvxpHdW7BOVKJeVYMpryT9tyOJqPxJgYpLzpe8Te07YrVcrhsiPg+HcjTEgcKPH/QeLfMYqNjXK+lM15Dkwue+PsFXJb+F0ozvIS3LDhsfjYsB9Ja/43Vu36F5qtLfi/3+6HoRdmk7iOPtst9V25yUTPqds/bOuz2nvJcbk7L/jr1d53dyq2oJ652lHoJ8coVR7PRwrxU8pqg5KVw5WHgHBT12vaC0GSAflT6Q+7rtP+lP0Pfdc6bSVH8xCvikfeUVu2348NBpiqDbAERJ6d+x6DcFU4JlCQU+9nh5Qgq9poD64sMFZTsHna0mFtcUl3lLqnetR2dxeSuzwI8IvaFkuzW2VNTc2oqalDS0srhg3T0HJWtPJ7R25KlzmjUqkQSzNZw4fHwNBYg5n/yMHSkgLUNJx1tqQd7Vi9u9SZH5CJ7VnQdeYmXWK3g6HS2SqoZg+UvnngBX/Atvc9a7urcjmyGA9XfvaHY9iF1QID8ZOhgTOyX2kICDd5vqK9ECTZHY/7E3YajTA69teT7AIvJ5MBV8x4xNn371C2VI+K11Kw7N9e+h1I8c1Z2NnUhJLHtYFYdav75z//GQ8//HC3er4VRNoTBPjH2TzZ8VdueUapttYccIBUXV2Ne+65R1maCw4OxrPPPksBV4uzGp7lTU1NVeQqlQqc5jKngpcEzySt27sNqRQgHTR5nmItrtqDCy3uQZ8Xd/1anLrBhZuMO5E11ldzTDRY8SW/gmR9xDEOhIRrHEgM/LNwk+dr1HtBUkgMtFptx65Rw/SPNNw4Oh7ZW22zIaY302hpKQUF7yyBbkY+zZ5UYdkUHZXZlpuUZaP787GreC50oY6RnAVVK8iO80TwqjjStU/TKPqTX0TRlrmIt8vjn9kF0+5lSAwne9LXzSmFXR3gGr34IqFzs2zNVtq9xCXQqfrvROgSqG5bV5y6SsLZdz2SUpOhoXos56F8lDaOJjslR4ft1Heasl7iNrqjck9b5+nt6o3IGG3rl8rDjJVx6xInDu79dnfOxBUfHy+BkjsslyXnjYgclXNgolKpHNluz1arFUuXLsWpU6ewe/du/POf/8Tf/vY3FBQUKLZNFGTPmzcPe/fuxdatW/HZZ5/h+uuvR3h4uCLv7jBeO8anCi+7/b8jFT51BoJQrXHhJq0GausuLPsZcQ/xjTJYo/ySOB0mPLMR/yc5AdmfAHgng7hJB9vykm3JK7u4CnlTwingjLfNgp8uxZIEzquojHTXVpEhbzb9uWvLkZesIxnJdcR9h0zYONueD01E3iHWte9efdnlyolmr5Oo3akFMCl5OjQUYS5xSspaZwkV+rl15hhrFQpS7e2j+zCG/Opot2Fg91lLfY6j/pBcpZuL0g6CtSt0nIRrOrAY6CnhJvsV6nTqvSDp9H6UflCEImWvUB5g7axcZGmrkL8wBxWWcuQsLIJl5jJkTslA/rzJ1BQtUp/LR/6rGYinHHjZaHs2EudXIuP1zSh7Lgn176QhnqaG418qw3eGMvwpMg/3PWwnCNangCjtGSBrYyGyJgJVr1Aw81AFktZsRu5MDUxvZiJ3LzuHb182FeWonpaK5NPU7o3lSh6oQOHru1A/ORlJanuR68nR93/kIW1WHupv/hOyptkVuI3O5TQqsxhpWY9GqhZKd7d1mt4ufS4DG0OyUGIw4rsvVyIjQQcNHB8i79frCQdHv9N8zmYJeTlwu3znixdbwF+v9VVjZGSEL3EX2ZkzZ/DFF18gMzMTd999N1JSUvC73/0O7777LhoaGrBv3z6Ul5djzZo1+M1vfoMpU6ZgxYoViI6O7uLLU8Evx96O8Vqf0y74V9UXnkwHVJnhcwc3FaH8ED186slY9kIKLMQ32e/Uw7R6MQUs8ch6KhW/XrQMqVpq/qRM4qZ8LJ6qo4yFZpdMyP8f8cjX5aDw/UJkjK2gQCsFeQ0Z2HzAiMr1idg5PxFLdoM+Nv2C+WkonZiHzS+nQmMqxdw4PXLUy7B5QxYSrLuwhIIyag1g9eWL3Dk3PdJm6mHaUoDN1bZCS3EBCqr1SJ7OjbaVuR5d+170QTkMrkKrxW0JrYowmbslHiuPNKHpyEpMoOW1mOk5dgxshlWvEMc9tdnepwKkLd9lE3g5Ctd4AWYAFQs3eb8YvRckmTYi++E0pCl7LvYrdeqxmKbq446/SIFRNvKRjsKXKDgalYDUKXrSiMGE6alIfSgBWsrZNjX9od+J3AWpSBpnRMGrpcCdS5A7Kx7h6nhkz08Gtpfb/bNFHHK3rkPWQ+lY+Vw6FyB9VQlyZqVi8eOkCxMopqBygx++SI23kCRk0bKZ5c0ilFup4OBmbDSpkZmeRBkPm6kIOU9nIeu5HBQdBdSRVGcPBnUePHct4mXK04BuYiYWz4pzkTtwoH4/lwUtLDCbXcQekkJeHkDpw6LufnskODgI/M9qA2lCMC2vqdVq/PDDD85f7h4+fDgMBgPOnz+vBFAxMTEYPXo0/v73v+Ptt98GB1aB1PHIT6b4VN9xohJt7e0+dfpbuOsVBzelIbvYqDRHPT0XBY+pUUqDsWSagY57eR0yR6kRNy0ZE64jFX0ScRPzkJoy9m3SSux8fzHSmbO25+NFWoVMfyEHiaQfMz0LmWPrUfq5SxgyqxBlL6QjdWkOlowjH+NzULImC6mzFiNjPOWJnJTW+OOL1HnTPp6NVOxC4RYmGQsNTIkjp2YibRRLu+6ufU97OI8su+o4SgzHqe3jk5F8sxrqm+lMbayCnri4A4O4l8uwjvg5dekyZGkBS303RAPgMnAN1SJbTxEQbvKOXO8FSeNz8R0RZbuyFyLZUee4LCyeDlTsrULCy3lIjnQIvJ310I92yKqwn2eBvlqGCfyyIe/ziRAc4s7nkM4FrvnAfMXNX4zJlnwUbAUMW4tgUGci45eu/lzSRHw7TxphPGlGu3kzUg8VIO2pjRSmuOj0QjL59TIsHleObFomCA+fgCWf1Hv2qolBjGeJlPYjAi0tHHF7b8DQoWrvQi+Sa6+9FtOmTcPq1avx0EMP4Ve/+hVee+01p3ZLS4vynuCvf/1rfPjhh3j66acxefJknDhxwqnTXeK3cT9HsMo7VTS1XMSxM8qf+u5c9Zs8/aN2JYhkfqqkAZCtIRqkPpUFzfEKVFgzsXIRD9xsEq/HW/SguEARGw7uVM4b02n5i7lJdx/yKGhSCrsc1FD74KeAfEWmI2uBGrvWFMJgLUfJFiDpsRRnuzpX7dr39vYSpHdWcMlPmJIEHCxA/icGGD4h/jsIpE5NdNFwTWoQQ8Gha4mkBycCwk3er5t35vNuE5jk38uwZGsckqaqUbE8B7t8/53o5DsOE2gkg0krYVSCLwfRFcIZhHWy8J4N0NeoNGROBTZ+UIDSrVXQLsrEZO/OOySaRCSx4hEjjM7SetT3xjdCNEnIraBpcGMZciZXIS8pExsvwS+P7iorK/H+++87WyqJvkOAAxZf3jv/NpEvXYdMpVIhLy8PH330EUaOHIlnnnkGzz//PPhHH4OCbI83zzRt3rxZCZJ46a22thYff/yxw0W352h1BOJH3OBT7z8/+h90uTnq14wJBc/lwTI1CXHWArzYzU9tdG6qflwCFamRVd7uDMDcgzAS+7kF6ispPRNqCmaK3ixFEbFh5mNaP2vyraZ9KAupajOKFiYicWEFEtdXovAxtW8jP6TCNX6A1I8qwk3ewbexqHe5/xLHezkf2Nf+t1fBwuvss/JhmZWLkg0rkVSfj4zlFTafIeF0rkLBOxUwmeqhrMtTifumR+ocIqLdy5DxCq2lm0wwHSRS2OtZ2922c84/X2bH74dAi4x5qcAH2TRjo0VmKrWjs0tH3mqmPnDbyrFxeQbpA/qZydCTPFyjo2M5Ct+porbTDNP8jZTvvFlQ76yXZBYKqix0dtvqUbp8CYoO0uyRlgKxiey3i5Kbha+MkJYvdHpfxv/rrK2t3afj0NAQn3JvQl5yS0lJweuvv46kpCTs2LED48aNU947iouLAwdJERG2d500Gg04XV9f782dx/LuXuA+VHvSo91AKXR/L6cIFdVA/TuZmPtJHHLWlKHgSQ3K59OgwwGLmlr+QSE2Hjd5H+BMzUCmxoL8+XPpuaTnn5bCKz4od3/nh9z4tfnjy1IPJ038MguLx1Zh2VMFsMzIQGqkX7V0q2RYuwxFdy5ByZdGGKvKsO5xun+6tfKtIFzjG5/+lgo3+b4CQb7FAUjd3klKQ9rTpfj8lQxasycSWp4M9ahMrHwpDob/TsMyXkKbthi5k4Cq5ROg06Wh0EFOnarULypH2SIdyp+5DzfylPYdKVj2UQUsnfT8yfrypZ+ZiQRU4cVZeXS0eVPTqCqLarKMzUTGRFuZx+OhF5GotO0+CuYMSHp5J/Yvj1NUtY8tRqbWgtL58dAl5EH/wp+oHkWkHJIey4SGxoIZC3kZMQkZj2soMMtA1la4f6wWWEylSLsjBvxbTImvNCF5TS7Se0COY8eOxSXOILm3TXLdItDW1uZTJyQkGCqVyqeON+G2bdvA32bjJbSXXnoJZWVl+MMf/qAER5MmTaLnS6cswZ07dw5btmzBjz/+qLzk7c2fp/Jxw5xr4J7EON14zmP5QCnc5fJOUtrDacj9dxGy5pRCTQO4rJuByS8UIF1diozZG1EPPTKXZ0Jr2YgMvQ765bvg8ROZjHW71iG5gQY/d+gI5xsx4al87DruUdt3oU9fSR54IQ7ZT0+GxWJB6mOp4JjOdwX+SfXTMxC3ewnir1FBpbLvyrfy/LPvrCVc0xmRgZcXbvJ9TXohSNJj8YF2t+lmnnJuP7AY056tpPJKLCYS4mbEKfnvkDORciFxWLyrHU21RpibymhEBuiXuuuTFm0aJL1K5U1m5d0Kc1M7Kl+YrJBCF/0ZhVRfOwpnkBlvnfPw7gs3L8b+Jqpj12LYwhs4P/pZRBzOnGvCQ9+bvsPmpZOhCbHrMfkZm2A2mtHUVInceTnYT0uHjjaqp6+D+bwZ5jWpZKBG8nrSqzWjgPtAbaokXeUdihAtUtc4cCCdFiNK5tla2gUHu52jDnLsth0/flyW2NwQ6ftMd0TkWBoLtCX8rB09ehQLFiwA/0H6y1/+gr/+9a+YMYNvIIBf4uYZJl5ei46Oxh//+Ee8/PLLuPfeewOqaliE72/D1TU1BOTvsinbOYBxct0LH01FYRPxz4ZkhUugseXbP0qHBoBmxjoYm4gPaunZfZXXz5NRSM9iO+mTuGMbl4kSI/mpNcJY24R242akj2VxZ329jSeJF3mGGeicJxuvvjrxAql2bKlIm6HuyLqm7H1354Fk937YuULhGNBg7tVcWJaWKVxrNFKfDuRiMg3O8ooNYI508pFSj97Wp86YKDLb4XYTBacAAAPSSURBVLhwjQ2IAXwUbnK9OF3TQV2LLm+J+jotNF6ecbeWqDXQav3UdTP0kPHmi8uVxphQsSUfS6akId+SjJyn4zw4CaRIDY1W4/3FzUgNNJFwftTXabzrqhkHH3KnF0kMJATaullqCwpS9ai5KpUKCxcuRGNjI3iGiM+cV6k6/PES3Pfff++UL1q0CCpVh9yfimOHXuNTzXzhvE/5oBTys3ad2q+mM49p/dTtzqE3X05eOFqOfJoZS3xqF/TPLkNPZpM9t6ECpe/Uw2yqBzRa4lsNULWfZtY1SByv82wipYMeAeEm35ew34Mk383rL2klCp/KQaE1GesO0MiQuKK/WiL1XhkI8D+yHTlyGLzt/C9ALqWnoaGhyqwRnz354feWeFZJrVZ7Endb9vPRt+K7/7Xe675l9vPd+hCF3kHAsD0POa9XQf98Cfa/kNA7ThUvk5FTuhj64jTolB/jDYf+ORMyi6qwbnrP7hvF7WU4SBU9R0C4yTd2EiR5xCcJufyV/i8LkTleyMEjRFIoCAgC/YKAfkEJjCcrUfZCMpzL+r3UEs3UXOw3tyuvLfDyZNORMuTO1PaSd3EjCAw+BIIGX5OlxYKAIHBlICC9EAQEAUFgYCMgQdLAvj7SOkFAEBAEBAFBQBDoJwQkSOon4AdztdJ2QUAQEAQEAUHgakCgS5DE69BXQ8elj4KAINA/CFwKx1yKbf/0VmoVBASBQYKA8i5e57a6BUn8g3ZWa2tnHckLAoKAINBrCDDHMNcE6pBt2DZQO9EXBAQBQcAfBJhfmGdcdd2CpCFDQtHc3OIql7QgIAgIAr2KAHMMc02gTtmGbQO1E/0rHAHpniDQSwgwvzDPuLpzC5KGDlWjsfGCxyknVyNJCwKCgCDQEwR4uYw5hrkmUHu2YVv2Eait6AsCgoAg4AsB5hXmF+YZVz23IIkjqLCwITh7tsFVR9KCgCAgCPQKAswtzDFDhoQG7E/4KWDIxEAQEAT8RMAbN7kFSexLo7kGra1tqK8/LzNKDIjsgoAgcMkI8CiNOYW5hTmmpw7Zln2wL/bZUz9iJwgIAoIAI8A8wnzCvML8wmWue5cgiYXXXmv7Z5Y1NXVoaGhCS4tVAiYGRnZAMBAE/ESAyYe5gzmEuYTNHNzC6Z7uDh/sk31zHVxXT/2JnSAgCFxdCDBfMG8wfzCPcO8dvMJp191jkMQKHFHFxETBarXCbD4Ho/E0fvihVnbBQO4BuQf8ugeYM5g7mEOYS5hTmFt6Y2df7JN9cx1cl/CT8LPcA3IP+HMPMF8wbzB/MI8wn3jjpf8PAAD//zIBJb0AAAAGSURBVAMA7spd5LSIS4sAAAAASUVORK5CYII=" width="585" height="56" alt="KZIA's Sentiment Meter and Message Volume as of 9:23 a.m. ET on Nov. 19, 2025 | Source: Stocktwits"><figcaption>KZIA's Sentiment Meter and Message Volume as of 9:23 a.m. ET on Nov. 19, 2025 | Source: Stocktwits</figcaption></figure><p>KZIA stock is down by 8% this year and by about 71% over the past 12 months.</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/alkermes-to-acquire-avadel-for-up-to-2.37-billion-after-lundbeck-proposal/cLPoIyoREB2">Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Rising stock market chart on a trading board background.

KZIA Stock Soars After Stage IV Cancer Patient Shows Initial Complete Remission On Its Drug Combination

Kazia now plans to conduct a follow-up scan to confirm the initial scan. 

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Current Price	$7.58
Prev Close	$8.45
Open	$7.85
Dividend Yield	0.00%
50-Day Moving Average	$6.89
Beta	1.30
Avg. Volume	290,176.95
PE Ratio	-0.69

52-Week High	$17.40
52-Week Low	$2.86
Market Capitalization	$14.12M
EPS (Annual)	-$12.23
Price to Book	-2.51
Revenue Per Employee	N/A

KZIA
Kazia Therapeutics

Feed

News

Sentiment

Fundamentals

Info

Latest KZIA News

KZIAKazia Therapeutics